Exact Sciences, Genomic Health report 12% MDxHealth (MDXH) ownership

Rhea-AI Filing Summary

MDxHealth SA received an updated ownership report showing that Genomic Health, Inc., a Delaware company and wholly owned subsidiary of Exact Sciences Corporation, beneficially owns a total of 6,441,171 ordinary shares of MDxHealth. This total includes 2,441,171 ordinary shares directly owned and warrants or contractual rights to purchase an additional 4,000,000 ordinary shares.

The filing states this represents 12.0% of MDxHealth’s ordinary shares, based on 49,497,334 ordinary shares issued and outstanding as described in MDxHealth’s Form F-3 registration statement filed on December 29, 2025. Exact Sciences may be deemed to beneficially own the shares held by Genomic Health, and the reporting persons certify that the securities are not held for the purpose of changing or influencing control of MDxHealth.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/16/2026 - 03:38 PM Learn about SEC filing dates

FAQ

How many MDxHealth (MDXH) shares are beneficially owned by Genomic Health and Exact Sciences?

They report beneficial ownership of 6,441,171 MDxHealth ordinary shares, consisting of 2,441,171 ordinary shares plus warrants/contractual rights to purchase 4,000,000 additional ordinary shares.

What percentage of MDxHealth’s outstanding shares do Genomic Health and Exact Sciences own?

The filing reports beneficial ownership of 12.0% of MDxHealth’s ordinary shares, based on 49,497,334 ordinary shares issued and outstanding.

How is Exact Sciences related to Genomic Health in this MDxHealth (MDXH) filing?

Genomic Health, Inc. is described as a wholly owned subsidiary of Exact Sciences Corporation. Exact Sciences may be deemed to beneficially own the MDxHealth ordinary shares directly owned by Genomic Health.

What type of MDxHealth securities are covered in this Schedule 13G/A?

The filing covers MDxHealth SA ordinary shares, no par value, with CUSIP B5950S113, including shares and certain warrants/contractual rights to purchase additional ordinary shares.

On what date was the ownership position in MDxHealth that triggered this Schedule 13G/A measured?

The date of the event requiring this Schedule 13G/A filing is stated as January 9, 2026.

Do Genomic Health and Exact Sciences seek to influence control of MDxHealth (MDXH) with these holdings?

The certification states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of MDxHealth, and are not held in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

MDxHealth SA

(Name of Issuer)

Ordinary shares, no par value

(Title of Class of Securities)

B5950S113

(CUSIP Number)

01/09/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. B5950S113

1

Names of Reporting Persons

Genomic Health, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 6,441,171.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 6,441,171.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,441,171.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

12.0 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: Row 11 is calculated based on 49,497,334 ordinary shares issued and outstanding as described in the Issuer's Registration Statement on Form F-3 filed with the U.S. Securities and Exchange Commission on December 29, 2025.

SCHEDULE 13G

CUSIP No. B5950S113

1

Names of Reporting Persons

Exact Sciences Corporation

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,441,171.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,441,171.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,441,171.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

12.0 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: Row 11 is calculated based on 49,497,334 ordinary shares issued and outstanding as described in the Issuer's Registration Statement on Form F-3 filed with the U.S. Securities and Exchange Commission on December 29, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: MDxHealth SA
(b)	Address of issuer's principal executive offices: CAP Business Center, Zone Industrielle des Hauts-Sarts, Herstal, C9, 4040
Item 2.
(a)	Name of person filing: (a) Genomic Health, Inc. (b) Exact Sciences Corporation
(b)	Address or principal business office or, if none, residence: (a) The business address of Genomic Health, Inc. is 5505 Endeavor Lane, Madison, WI 53719 (b) The business address of Exact Sciences Corporation is 5505 Endeavor Lane, Madison, WI 53719
(c)	Citizenship: (a) Genomic Health, Inc. - Delaware (b) Exact Sciences Corporation - Delaware
(d)	Title of class of securities: Ordinary shares, no par value
(e)	CUSIP No.: B5950S113
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of the date hereof, Genomic Health, Inc. owns 2,441,171 Ordinary Shares and warrants/contractual rights to purchase an additional 4,000,000 Ordinary Shares of the Issuer. Genomic Health, Inc. is a wholly owned subsidiary of Exact Sciences Corporation. Exact Sciences Corporation, through the ownership described herein may be deemed to beneficially own the Ordinary Shares directly owned by Genomic Health, Inc.
(b)	Percent of class: See responses to Item 11 on the attached cover pages.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See responses to Item 5 on the attached cover pages.
	(ii) Shared power to vote or to direct the vote: See responses to Item 6 on the attached cover pages.
	(iii) Sole power to dispose or to direct the disposition of: See responses to Item 7 on the attached cover pages.
	(iv) Shared power to dispose or to direct the disposition of: See responses to Item 8 on the attached cover pages.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Genomic Health, Inc.

Signature:	/s/ James Herriott
Name/Title:	James Herriott, Secretary
Date:	01/16/2026

Exact Sciences Corporation

Signature:	/s/ James Herriott
Name/Title:	James Herriott, Senior Vice President, General Counsel and Secretary
Date:	01/16/2026

Exhibit Information

See Exhibit 99.1 for Joint Filing Agreement, dated as of January 16, 2026, by and among the Reporting Persons